(Q27077698)

PubChem

PubChem CID

5282448

Fondaparinux (English)

20 November 2016

isomeric SMILES

CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O

1 reference

parenteral route of administration

14 February 2018

2.5 milligram

route of administration

1 reference

reference URL

https://www.whocc.no/atc_ddd_index/?code=B01AX05

1 reference

14 February 2018

medical condition treated

thrombosis

1 reference

2 October 2018

atrial fibrillation

1 reference

2 October 2018

thrombophlebitis

1 reference

2 October 2018

phlebitis

1 reference

2 October 2018

pulmonary embolism

1 reference

significant drug interaction

2 October 2018

enoxaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dalteparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

urokinase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alteplase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenecteplase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Streptokinase

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clopidogrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eptifibatide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

iloprost

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prostacyclin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tirofiban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aceclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prasugrel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ticagrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cangrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

abciximab

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Serpin family C member 1

subject has role

activation

1 reference

Open _targets Platform

https://platform.open_targets.org/drug/CHEMBL1201202

14 August 2023

reference URL

LiverTox likelihood score

LiverTox toxicity likelihood category E

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Fondaparinux

6 February 2018

1 reference

5 March 2018

1 reference

Medical Subject Headings

15 March 2018

Fondaparinux.svg
833 × 372; 78 KB

0 references

NCI Thesaurus ID

C73142

1 reference

UNII

J177FOW5JL

InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6(74-27)3-71-88(57,58)59)76-31-22(83-91(66,67)68)16(40)21(24(81-31)26(43)44)79-29-10(34-86(51,52)53)19(82-90(63,64)65)18(7(75-29)4-72-89(60,61)62)77-30-15(39)14(38)20(23(80-30)25(41)42)78-28-8(32-84(45,46)47)12(36)11(35)5(73-28)2-70-87(54,55)56/h5-24,27-40H,2-4H2,1H3,(H,41,42)(H,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18-,19-,20+,21+,22-,23+,24-,27+,28-,29-,30-,31-/m1/s1

14 February 2018

Identifiers

InChI

1 reference

based on heuristic

inferred from SMILES

InChIKey

KANJSNBRCNMZMV-ABRZTLGGSA-N

2 references

Fondaparinux (English)

20 November 2016

14 February 2018

3 references

fondaparinux (English)

19 October 2016

KANJSNBRCNMZMV-ABRZTLGGSA-N

14 February 2018

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=104993-28-4

1 reference

Methyl 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1->4)-beta-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1->4)-2-O-sulfo-alpha-L-idopyranuro (English)

20 November 2016

2 references